MediWound

MediWound offers next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, the Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries. MediWound’s first product, NexoBrid, is a commercial, FDA approved orphan biologic drug for early non-surgical eschar removal of deep-partial and full-thickness thermal burns. It is a bromelain-based gel containing a sterile mixture of proteolytic enzymes that selectively removes burn eschar within four hours without harming surrounding viable tissue. EscharEx is MediWound’s leading biologic currently in development, utilizing the same active pharmaceutical ingredient found in NexoBrid. It is specifically designed for the debridement of chronic and hard-to-heal wounds. MW005 is an innovative topical biological drug currently in development to address the treatment needs of low-risk Basal Cell Carcinoma (BCC).

MediWound has raised $198.72M in total funding across 8 rounds. The company is currently at the Public stage. Key investors include Mölnlycke Health Care, Yalin Lapidot, Israel Biotech Fund.

MediWound was founded in 2000 by Marian Gorecki, Ph.D. (Co-founder), Lior Rosenberg, M.D. (Co-founder & CMO), Andrey Kon, M.Sc. (Co-founder & VP Plant Manager).

MediWound operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Biomaterials & Tissue Engineering, Drugs Discovery & Development, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Healthcare, Patients, Life Sciences, Pharmaceuticals.

MediWound is based in 42 Hayarkon Street, Yavne, Israel, Center District. The company also has offices abroad.